Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

NOVATO, Calif., April 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced the appointment of Patrice P. Rioux, M.D., Ph.D., as Chief Medical Officer ("CMO"). Dr. Rioux will be responsible for the clinical and regulatory advancement of Raptor's clinical-stage drug development programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

Raptor's clinical programs include Delayed-Release Cysteamine ("DR Cysteamine") for the potential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's Disease ("Huntington's"), as well as Convivia(TM), for the potential treatment of aldehyde dehydrogenase ("ALDH2") deficiency.

Dr. Rioux has extensive experience as a clinician, researcher, medical director and regulatory specialist. Most recently, Dr. Rioux was CMO of FerroKin Biosciences, an early-stage developer of iron chelator for treatment of anemias. Prior to that, he was CMO and Vice President Clinical/Regulatory for Edison Pharmaceuticals, which focused on developing drugs to treat inherited and acquired energy impairment diseases. Dr. Rioux' three-decade career includes industry experience at companies such as Repligen Corp., Arrow International, Variagenics, Inc., Biogen and GRP (Groupement de Recherche en Pharmacologie). He previously was a researcher in Clinical Research and Epidemiology at INSERM (Institut National de la Sante et de la Recherche Medicale), a French organization that supports national research in the medical field, from 1975 to 1995. Educated in France, Dr. Rioux has an M.D., a Ph.D. in Mathematical Statisics, and a Masters in Pharmacology.

Christopher M. Starr, Ph.D.,
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Colo. , Aug. 22, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... iCare,s third international medical cannabis conference taking place ... Strasbourg, France , on October 22, 2014.  ... other stakeholders, such as researchers, health professionals, and ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... , Aug. 21, 2014  Aptuit LLC ... West Lafayette, Indiana , has enhanced its ... characterization of small and large molecules, including biologic ... the Bruker maXisPlus Q-TOF mass spectrometer. ... , CEO, Aptuit, said, "The expanded large molecule ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
... Mass., May 20, 2011 Philips ... Philips FilterLine H Set and VitaLine H Set ... November 2010 through March 2011.ProductProduct DescriptionProduct Lot CodesM1923A ... M8330M10M8386N10M8411P10M8451P10M8477A11M8514A11M8572B11989803159581 , Philips Vitaline H Set Infant/Neo ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2
(Date:8/22/2014)... FL (PRWEB) August 22, 2014 ... treatment facility in Lantana, FL, recently launched a ... just looking for information can now find Millennium ... new website just went live at the beginning ... about the facility can be found on the ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
(Date:8/22/2014)... in advanced non-small cell lung cancer (NSCLC) is ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... deletion independently predicts overall survival (OS) of advanced ... the programmed cell death also known as the ... detected in 12.8% of the Asian population but ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... August 22, 2014 Paying tuition and ... in the coming year for four nurse educators pursuing ... National League for Nursing Foundation for Nursing Education . ... share $28,000, $10,000 more than in 2013, thanks to ... Endowment and Elizabeth Isaac Marcil Endowment Funds, both donated ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
... has been aroused in the identification and isolation of ... of bone marrow cells have been found to have ... on immunological methods is difficult because of the complicated ... of successful passage has been published., A research article ...
... , , WEDNESDAY, April 15 (HealthDay News) -- If you have ... or pop in a CD of mellow songs. , Hospital ... rate and blood pressure just by listening to music, a ... report, published in the latest issue of The Cochrane ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... PM Eastern Time on Wednesday, April 22, 2009. Richard ... will host the call.(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... parties may dial (888) 790-3326 (U.S./Canada) and use Conference ...
... MOUNTAIN VIEW, Calif., April 15 Based on ... tomography (PET) and PET/computed tomography (CT) markets market, ... the 2009 North American Frost & Sullivan Award ... forth innovative scintillation crystal and solid-state photo detector ...
... CITRUS HEIGHTS, Calif., April 15 In response ... (EHR) for all patients, SMART Association, Inc. and ... their LifeMed(TM) Smart Card Platform software for EHRs. ... ("HIEs"), hospital legacy systems, or physicians, record management ...
... need to evaluate options for continuing healthcare coverage , ... ... the 2009 American Recovery and Reinvestment Act (ARRA) may be crucial ... people with disabilities no longer able to work, according to ...
Cached Medicine News:Health News:Soothing Songs Please the Heart 2Health News:Delcath Systems to Host Quarterly Update Conference Call 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 3Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 4Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 2Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 2Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 4
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: